Industrial Information Technology Engineer
About the job
- Higher education from Bac+2 to Bac+5 in industrial information technology.
- Approximately 10 years of experience in industrial process automation, preferably in the pharmaceutical industry.
- Experience with programmable logic controller programming, TIA Portal, STEP 7, WinCC, Machine Expert, batch management systems, and manufacturing execution systems.
- Knowledge of Siemens systems, particularly PCS7, is an advantage.
- Experience in project management from studies through commissioning.
- Knowledge of project-management software, including Excel and Microsoft Project.
- Knowledge of the regulatory environment applicable to the pharmaceutical industry, including qualification procedures, Good Manufacturing Practices, current Good Manufacturing Practices, and 21 CFR Part 11.
- Administer systems within the assigned scope and maintain installations in operational condition according to established procedures.
- Analyze process or information-technology malfunctions, provide technical expertise to internal customers, clarify problematic situations, and propose solutions.
- Design, develop, and participate in the qualification of systems.
- Comply with equipment availability and reliability requirements and rates.
- Contribute to projects by participating in technical direction and preparing technical specifications in collaboration with new-construction and engineering departments.
- Basic knowledge of instrumentation.
- Experience in maintenance.
About the company
LFB is a French biopharmaceutical company that develops and manufactures medicines from plasma and biotech products. It collects plasma, fractionates it into medicines, and also produces recombinant proteins for rare diseases in immunology and hemostasis, sold in many countries. It stands out because it started as a state-initiated public health mission and remains state-owned with the French State as sole shareholder, plus vertical integration through acquisitions of plasma collection firms. Its goal is to ensure a reliable supply of essential medicines for public health while growing as a global biopharma player.
Company Size
1,001-5,000
Company Stage
N/A
Total Funding
N/A
Headquarters
Courcebœufs, France
Founded
1994
Get referred to LFB
See people who can refer or advise you
Simplify's Take
What believers are saying
- Arras released first medicines in 2025, proving commercialization after heavy capital spending.
- LFB signed a 2026 collaboration with Sartorius to accelerate client programs and GMP manufacturing.
- France 2030 funding and the 2026 Alès expansion add capacity and roughly fifty jobs.
What critics are saying
- EFS must raise plasma collections to 1.4 million liters by 2028 or Arras underutilizes.
- LFB BIOMANUFACTURING still depends on Sartorius for cell line development, limiting full-stack control.
- A single French industrial base creates existential exposure to contamination, recalls, or regulatory shutdowns.
What makes LFB unique
- French state-owned sole domestic plasma fractionator anchors national medicine supply.
- Arras plant, authorized in 2025, centralizes production and triples plasma-derived capacity.
- Europlasma and Amber Plasma give LFB 24 Central European collection centers.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
401(k) Retirement Plan
Remote Work Options
Unlimited Paid Time Off
Flexible Work Hours
Paid Vacation
Hybrid Work Options
Wellness Program
Mental Health Support
Phone/Internet Stipend
Home Office Stipend
Stock Options
Company Equity
Conference Attendance Budget
Family Planning Benefits
Fertility Treatment Support
Professional Development Budget
Education allowance
Tuition Reimbursement
Growth & Insights and Company News
6 month growth
8%1 year growth
8%2 year growth
7%Title: "LFB Acquires Amber Plasma in the Czech Republic" LFB and its subsidiary Europlasma have acquired Amber Plasma, which operates 12 plasma collection centers in the Czech Republic. This acquisition increases Europlasma's total to 24 centers in Central Europe, enhancing LFB's plasma collection capacity. The move supports LFB's goal to meet growing patient demand and will aid in the launch of a new production site in Arras, France, tripling its medication production capacity.